Inspira Receives U.S. Patent Approval for the ART500 Core Technology, Key Patent Positions the Company to Dominate $20 Billion Estimated Market

Rhea-AI Summary

Inspira Technologies (NASDAQ: IINN) has secured a crucial U.S. patent for its ART500 core technology, featuring low flow rates extracorporeal oxygenation system. The patent, which includes 16 novel claims and extends protection until 2043, positions Inspira to target an estimated $20 billion market for advanced respiratory support.

The ART500 system represents a breakthrough in respiratory care, designed for conscious, spontaneously breathing patients who need support but may not require traditional high-flow ECMO systems. This innovation creates a new therapeutic category, bridging a significant gap in current treatment options.

Positive

• Patent protection secured until 2043 for core ART500 technology
• Technology targets estimated $20 billion market opportunity
• Creates new therapeutic category for underserved patient population
• ART100 system already generating commercial momentum
• Company pursuing additional patents globally

Negative

• None.

Insights

Medical Device Patent Specialist

Inspira's patent for low-flow extracorporeal oxygenation strengthens IP portfolio and market position in a massive potential market.

Inspira Technologies has secured critical intellectual property protection with this newly approved U.S. patent covering their ART500 core technology for low-flow extracorporeal oxygenation. The patent includes 16 novel claims and extends protection until at least 2043, providing the company with nearly two decades of market exclusivity for this technology.

What makes this patent particularly valuable is how it addresses an underserved patient population. Traditional ECMO (Extracorporeal Membrane Oxygenation) systems typically operate at high flow rates and are reserved for the most critically ill patients. The ART500's ability to provide extracorporeal oxygenation at lower flow rates while maintaining safety opens treatment to patients who need respiratory support but aren't sick enough for traditional ECMO – effectively creating a new therapeutic category for conscious, spontaneously breathing patients.

This patent strengthens Inspira's competitive positioning in two key ways: first, by protecting the core technology that enables their entry into this $20 billion estimated market; and second, by complementing their existing ART100 system which is already being commercialized. The extended protection period gives Inspira significant runway to build market share before facing potential direct competition.

The company's strategy of pursuing additional patents in major global jurisdictions indicates a comprehensive approach to IP protection that aligns with potential international market expansion plans. This multi-layered IP strategy significantly enhances the company's ability to maintain technological leadership in advanced extracorporeal life support systems.

RA'ANANA, Israel, Aug. 22, 2025 (GLOBE NEWSWIRE) -- Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ: IINN) ("Inspira," “Inspira Technologies,” or the "Company"), a pioneer in innovative life-support and diagnostic technologies, has received U.S. Patent approval for low flow rates extracorporeal oxygenation system and methods of use. This patent represents the core technology of the ART500 device, a key asset in the Company’s strategy to penetrate the $20 billion estimated market for advanced respiratory support. This innovation has 16 claims found to be novel.

The patent provides further protection for the underlying core technology of Inspira’s ART500 system, which is designed to provide extracorporeal oxygenation at low flow rates while maintaining patient safety and treatment efficiency. This capability targets a large, underserved patient population that requires respiratory support but may not be sick enough for traditional, high-flow ECMO systems, significantly expanding the potential market for Inspira's technology. This approval strengthens Inspira’s intellectual property portfolio and reinforces the Company’s technological leadership in the field of advanced extracorporeal life support.

Dagi Ben-Noon, Chief Executive Officer of Inspira Technologies, stated: "This patent has profound business implications for Inspira and for our ability to dominate a market with a potential size of $20 billion. We are creating a new therapeutic category for conscious, spontaneously breathing patients. Protecting our intellectual property is a critical pillar of our growth strategy, and this patent approval provides us with a distinct competitive advantage. While our ART100 system is already generating commercial momentum, this move fortifies our future and gives us the clear runway needed to translate our technological leadership into long-term value for our shareholders, and a new standard of care for patients worldwide."

The newly received patent provides protection at least until the year 2043, covering key claims related to the ART500’s functionality, design, and clinical applications. Inspira is pursuing additional patents in major jurisdictions worldwide to expand its intellectual property coverage.

About Inspira Technologies

Inspira Technologies is a commercial-stage medical device company specializing in advanced respiratory support and real-time blood monitoring solutions. The Company’s U.S. Food and Drug Administration -cleared INSPIRA™ ART100 system is approved for cardiopulmonary bypass in the U.S. and ECMO (Extracorporeal Membrane Oxygenation) procedures outside the U.S and serves as a foundation for the development of the INSPIRA ART500, a next-generation system designed to deliver oxygenation while patients remain awake and spontaneously breathing. Inspira Technologies is also advancing HYLA™, a proprietary blood sensor platform offering continuous, non-invasive monitoring. With multiple cleared products, a growing IP portfolio, and strategic streamlining of its operations, Inspira Technologies is increasingly positioned as an attractive platform within the life-support and MedTech landscape. The Company’s recent internal shifts may reflect broader alignment with long-term industry trends, including consolidation, cross-sector collaboration, and potential strategic partnerships. For more information, visit: https://inspira-technologies.com

Forward-Looking Statement Disclaimer

This press release contains express or implied forward-looking statements pursuant to U.S. Federal securities laws. These forward-looking statements are based on the current expectations of the management of the Company only and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. For example, the Company is using forward-looking statements when it discusses that the patent protects its core technology underlying the ART500 system, that the approval strengthens its intellectual property portfolio and reinforces its technological leadership in the field of advanced extracorporeal life support, that the patent is a clear validation of the innovation at the core of the ART500, that the patent approval provides its with a distinct competitive advantage, that the patent approval fortifies its future and gives it the clear runway needed to translate its technological leadership into long-term value for both patients and shareholders, and that it is pursuing additional patents in major jurisdictions worldwide to expand its intellectual property coverage. These forward-looking statements and their implications are based solely on the current expectations of the Company's management and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Except as otherwise required by law, the Company undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. More detailed information about the risks and uncertainties affecting the Company is contained under the heading "Risk Factors" in the Company's annual report on Form 20-F for the fiscal year ended December 31, 2024, filed with the U.S. Securities and Exchange Commission (the "SEC"), which is available on the SEC's website at www.sec.gov.

Company Contact
Inspira Technologies – Media Relations
Email: info@inspirao2.com
Phone: +972-9-9664485

FAQ

What patent did Inspira Technologies (NASDAQ: IINN) receive in August 2025?

Inspira received U.S. patent approval for its low flow rates extracorporeal oxygenation system, which is the core technology of the ART500 device. The patent includes 16 novel claims and provides protection until 2043.

What is the market size potential for Inspira's ART500 technology?

The ART500 technology targets an estimated $20 billion market for advanced respiratory support.

How does Inspira's ART500 differ from traditional ECMO systems?

The ART500 is designed for conscious, spontaneously breathing patients who need respiratory support but may not require traditional high-flow ECMO systems, creating a new therapeutic category for an underserved patient population.

What is the duration of Inspira's new patent protection for the ART500?

The patent provides protection for Inspira's ART500 technology at least until the year 2043.

What are Inspira's plans for international patent protection?

Inspira is actively pursuing additional patents in major jurisdictions worldwide to expand its intellectual property coverage for the ART500 technology.